Market Overview

Deutsche Bank Reiterates Buy on Onyx Pharmaceuticals on Updated Guidelines

Related ONXX
How to Prepare for the New Year
UPDATE: Stifel Terminates Coverage on Onyx Pharmaceuticals Following Acquisition by Amgen

In a report published Monday, Deutsche Bank reiterated its Buy rating and $105.00 price target on Onyx Pharmaceuticals (NASDAQ: ONXX).

Deutsche Bank noted, “Guidelines updated on Friday add Kyprolis in combo with Revlimid & Dex as an option for patients who are transplant candidates with a category 2A classification (low-evidence but uniform NCCN consensus). It has been included as an ‘other regimen.' We are not sure what differences there are in other vs. preferred for ease of reimbursement, but we think that inclusion as other is definitely a positive first step.”

Onyx Pharmaceuticals closed on Friday at $85.65.

Latest Ratings for ONXX

Nov 2013Stifel NicolausTerminates
Aug 2013Maxim GroupDowngradesBuyHold
Aug 2013Summer StreetDowngradesBuyNeutral

View More Analyst Ratings for ONXX
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Reiteration Analyst Ratings


Related Articles (ONXX)

View Comments and Join the Discussion!